Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72

Oncogene

Volumn 27, Issue 19, 2008, Pages 2788-2794

  Reinbold, M ^a   Luo, J L ^b   Nedelko, T ^a   Jerchow, B ^c   Murphy, M E ^d   Whibley, C ^e   Wei, Q ^a   Hollstein, M ^a,e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Embryonic fibroblasts; Lung cancer; Mutation hotspot; Polymorphism; Senescence

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; PROTEIN P53;

ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FIBROBLAST; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG TUMOR; MISSENSE MUTATION; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; TOBACCO;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TRANSFORMED; CODON; GENES, P53; HETEROZYGOTE; HUMANS; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

MUS; NICOTIANA TABACUM;

EID: 42549126097     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210932     Document Type: Article

References (29)

1. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A et al. (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133-1141.
2. Chen JX, Zheng Y, West M, Tang M-s. (1998). Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res 58: 2070-2075.
3. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW et al. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28: 289-298.
4. Denissenko MF, Chen JX, Tang MS, Pfeifer GP. (1997). Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc Natl Acad Sci USA 94: 3893-3898.
5. Denissenko MF, Pao A, Pfeifer GP, Tang M. (1998). Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 16: 1241-1247.
6. Denissenko MF, Pao A, Tang M, Pfeifer GP. (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432.
7. Dumont P, Leu JI, Della PA, George DL, Murphy M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
8. Feng Z, Hu W, Hu Y, Tang MS. (2006). Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 103: 15404-15409.
9. Hahn WC, Weinberg RA. (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
10. Hainaut P, Hollstein M. (2000). p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137.
11. Hainaut P, Pfeifer GP. (2001). Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22: 367-374.
12. Harvey DM, Levine AJ. (1991). P53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5: 2375-2385.
13. Hu Y, McDermott MP, Ahrendt SA. (2005). The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11: 2502-2509.
14. Liu Z, Belharazem D, Muehlbauer KR, Nedelko T, Knyazev Y, Hollstein M. (2007). Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. Genet Eng (NY) 28: 45-54.
15. Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. (2004). Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA 101: 2963-2968.
16. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC. (2005). p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65: 2583-2587.
17. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. (2001). Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20: 320-328.
18. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54.
19. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. (2005). TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 26: 1770-1773.
20. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
21. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. (2003). Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747.
22. Pfeifer GP, Hainaut P. (2003). On the origin of G to t transversions in lung cancer. Mutat Res 526: 39-43.
23. Pietsch EC, Humbey O, Murphy ME. (2006). Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
24. Song H, Hollstein M, Xu Y. (2007). P53 gain-of-function cancer mutants induce genetic instability by inactivating ataxia-telangiectasia mutated. Nat Cell Biol 9: 573-580.
25. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234.
26. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G et al. (2006). Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52: 9-14.
27. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100.
28. vomBrocke J, Schmeiser HH, Reinbold M, Hollstein M. (2006). MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27: 2141-2147.
29. Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A. (2001). Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84: 226-231.